Curaleaf Holdings (CURLF) Non-Current Deffered Revenue (2023)

Curaleaf Holdings (CURLF) recorded quarterly Non-Current Deffered Revenue of $40.2 million in Q3 2023, little changed quarter-over-quarter from $40.2 million in Q2 2023.

Curaleaf Holdings (CURLF) Non-Current Deffered Revenue (2023) Analysis & Trends

Curaleaf Holdings' Non-Current Deffered Revenue history runs 1 years deep, the most recent figure standing at $40.2 million for Q3 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Teva Pharmaceutical Industries 39.97 Bn 36.23 Bn 1.97 Bn -
2 Zoetis 33.59 Bn 31.65 Bn 1.62 Bn -
3 United Therapeutics 23.75 Bn 21.60 Bn 648.10 Mn -
4 Neurocrine Biosciences 16.10 Bn 14.78 Bn 800.70 Mn -
5 Aurora Cannabis 15.56 Bn 15.47 Bn 21.72 Mn -
6 Elanco Animal Health 12.04 Bn 11.61 Bn 785.00 Mn -
7 Alkermes 7.36 Bn 6.84 Bn -116.06 Mn -
8 Lantheus Holdings 6.74 Bn 6.24 Bn 230.92 Mn -
9 Liquidia 6.27 Bn 6.04 Bn 121.79 Mn -
10 Curaleaf Holdings - - 157.29 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2023 40.22 Mn
Jun 30, 2023 40.22 Mn